By Chris Wack
Shares of Telomir Pharmaceuticals climbed up 20% to $5.10 after the company said it saw positive pre-clinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several key parameters of Type 2 diabetes mellitus.
The pre-clinical stage pharmaceutical company said the study demonstrated significant reductions in fasting plasma glucose levels to basal levels, improvements in oral glucose homeostasis, and the reversal of insulin resistance to near pre-diabetic levels.
The Miami company said that these effects were also accompanied by increased survival rates in treated subjects, highlighting Telomir-1's ability to potentially address the underlying mechanisms of Type 2 diabetes.
Telomir had its initial public offering in February, with 1 million shares pricing at $7 a share.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 03, 2024 12:04 ET (17:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。